The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | U2′ regimen with checkpoint inhibition in R/R CLL and Richter’s transformation
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, highlights data from the Phase I/II triple therapy study of umbralisib and ublituximab (‘U2’) combined with checkpoint inhibition in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
